Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009824 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT04009824 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 51 participants.
The verdict
NCT04009824, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.
Interventions
- BIOLOGICAL AGS-v PLUS Vaccine
- BIOLOGICAL Montanide ISA-51 Adjuvant
- BIOLOGICAL Alhydrogel® Adjuvant
- BIOLOGICAL Saline Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2021-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04009824
The ClinicalTrials.gov registry entry for NCT04009824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AGS-v PLUS Vaccine is the first listed.
NCT04009824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04009824 about?
NCT04009824 is a clinical study titled "Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine". The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.
What is the current status of trial NCT04009824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2019-07-08. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT04009824?
The interventions under investigation include: AGS-v PLUS Vaccine (BIOLOGICAL), Montanide ISA-51 Adjuvant (BIOLOGICAL), Alhydrogel® Adjuvant (BIOLOGICAL), Saline Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04009824?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.